Premium
O4–03–07: Efficacy of rosiglitazone (RSG) in patients with mild to moderate Alzheimer's disease (AD)
Author(s) -
Hosford David A.,
Altman Jill F.B.,
Saunders Ann M.,
Risner Marc E.,
Zvartau-Hind Marina E.,
Ormandy George C.,
Roses Allen D.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.315
Subject(s) - medicine , placebo , apolipoprotein e , population , dementia , gastroenterology , disease , pathology , alternative medicine , environmental health
The average score for placebo . at the initial stage was 21.43 with SD 2.37 and after 3 months this score was 20.11 with the SD of 2.61 . This score, significantly varies with the p 0.000078 . i.e p 0.05. This reveals the fact, that the untreated patients show significant decline in the MMSE Score, confirming the necessity of management of vascular dementia. The Gr A and Gr B were compared for the study of drug efficacy. Gr A patients’ score at the initial level was 20.31 with SD 3.26 and at final stage it was 25.42 with SD of 3.47.